AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antismoking vaccine undergoes second clinical trial.
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Xenova Group plc (XNVA) has initiated a second clinical trial for TA-NIC, its therapeutic vaccine that is under development for the treatment of nicotine addiction.
This second phase I study builds upon the findings of a previous phase I trial, which were announced in June 2002. The results of this first study, which was the first evaluation of an anti-nicotine vaccine in man, showed that the vaccine generated a specific anti-nicotine response and that it was safe and well tolerated both systemically and locally.
The objective of the new phase I trial is to further establish safety and tolerability, and to determine the vaccination dose and schedule required to induce the optimal anti-nicotine antibody response. Three different doses of the vaccine will be evaluated. The impact of vaccination on nicotine-induced changes in heart rate and skin temperature will also be ...
- Xenova Group plc; Xenova Demonstrates Clear Clinical Responses in a...
- Press release article from: PR Newswire April 14, 2003 700+ words
Xenova Group plc (Nasdaq: XNVA; London Stock Exchange: XEN) today announced...and indicated that further development is warranted. Notes to Editors Xenova Group plc's product pipeline focuses principally on the therapeutic areas...
- Xenova Group plc: XR9576 Phase II Cancer Program Update Further Positive Phase...
- Press release article from: PR Newswire October 18, 2000 700+ words
...PRNewswire/ -- Xenova Group plc (Nasdaq: XNVA...update for its Phase II clinical trial candidate, XR9576...Executive Officer of Xenova Group plc said: "Multi...shown by XR9576." Xenova Group plc is a London Stock...
- Xenova Group plc First Quarter 1997 Financial Results 'In Line with...
- Press release article from: PR Newswire May 13, 1997 700+ words
...May 13 /PRNewswire/ -- Xenova Group plc (Nasdaq-NNM: XNVAY...reflecting an increase in clinical trial and drug development activity...Warner-Lambert and Zeneca. XENOVA GROUP PLC Consolidated Statements...attributable to members of Xenova Group plc $(4,284) (2,612...
- Xenova Group plc Successful Results of Phase IIa Trial For Therapeutic Vaccine...
- Press release article from: PR Newswire March 27, 2002 700+ words
...SLOUGH, England -- Xenova Group plc (Nasdaq: XNVA...II 'Prime-Boost' clinical trial in conjunction with...Notes to Editors Xenova Group plc's product pipeline...Communications, all of Xenova Group plc, +44-0-1753...
- Xenova Group plc Interim Results Announcement 1997
- Press release article from: PR Newswire August 14, 1997 700+ words
...K., Aug. 14 /PRNewswire/ -- Xenova Group plc (Nasdaq, London: XNVAY), the...six month period to June 30, 1997. XENOVA GROUP plc Six months ended June 30 (in 000...Xenova Discovery Limited, and joined the Xenova Group Board. During the period, the Group...
- Xenova Group plc First Quarter 1998 Financial Results; 'A time of substantial...
- Press release article from: PR Newswire May 14, 1998 700+ words
...PRNewswire/ -- Xenova Group plc (London Stock...due to an increase in clinical trial and drug development...Notes To Editors Xenova Group plc is an emerging...attributable to members of Xenova Group plc (4,452) (2...
- Xenova Group plc Third Quarter Results.
- Press release article from: PR Newswire November 6, 2003 700+ words
...start of Phase I clinical trial of novel DNA targeting...start of second Phase I clinical trial for anti-smoking...start of Phase IIb clinical trial for anti-cocaine...Notes to Editors Xenova Group plc's product pipeline...
- Xenova Group plc - First Quarter Results 1999 'Realizing the Strategic...
- Press release article from: PR Newswire May 13, 1999 700+ words
...England, May 13 /PRNewswire/ -- Xenova Group plc (Nasdaq: XNVA; London...1998 and including an increase in clinical trial expenditure due to the establishment...in the future." Contacts: UK Xenova Group plc Tel: +44
Source: HighBeam Research, Antismoking vaccine undergoes second clinical trial.